Mark W. Kroll Sells 7,118 Shares of Haemonetics Corporation (HAE) Stock

Haemonetics Corporation (NYSE:HAE) Director Mark W. Kroll sold 7,118 shares of the business’s stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $63.00, for a total transaction of $448,434.00. Following the sale, the director now directly owns 33,881 shares of the company’s stock, valued at $2,134,503. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Haemonetics Corporation (HAE) opened at $61.76 on Friday. The stock has a market cap of $3,308.01, a P/E ratio of 772.10, a P/E/G ratio of 4.71 and a beta of 0.99. The company has a debt-to-equity ratio of 0.22, a quick ratio of 1.51 and a current ratio of 2.17. Haemonetics Corporation has a 1-year low of $36.44 and a 1-year high of $63.90.

Haemonetics (NYSE:HAE) last issued its quarterly earnings data on Tuesday, November 7th. The medical instruments supplier reported $0.48 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.41 by $0.07. The firm had revenue of $225.40 million during the quarter, compared to analysts’ expectations of $219.12 million. Haemonetics had a net margin of 0.50% and a return on equity of 11.16%. The business’s revenue for the quarter was up 2.3% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.38 earnings per share. equities analysts forecast that Haemonetics Corporation will post 1.7 EPS for the current year.

A number of research analysts recently issued reports on the stock. Raymond James Financial upgraded shares of Haemonetics from an “underperform” rating to a “market perform” rating in a report on Tuesday. Morgan Stanley upgraded shares of Haemonetics from an “equal weight” rating to an “overweight” rating and set a $51.00 price objective for the company in a report on Tuesday. Zacks Investment Research cut shares of Haemonetics from a “buy” rating to a “hold” rating in a report on Monday, November 20th. Craig Hallum restated a “hold” rating and set a $50.00 price objective (up previously from $40.00) on shares of Haemonetics in a report on Wednesday, November 8th. Finally, Barrington Research boosted their price objective on shares of Haemonetics from $48.00 to $57.00 and gave the company an “outperform” rating in a report on Wednesday, November 8th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and four have assigned a buy rating to the company’s stock. Haemonetics has an average rating of “Hold” and an average price target of $53.33.

Several institutional investors have recently added to or reduced their stakes in the company. Tudor Investment Corp ET AL boosted its holdings in shares of Haemonetics by 0.5% in the second quarter. Tudor Investment Corp ET AL now owns 28,126 shares of the medical instruments supplier’s stock valued at $1,111,000 after buying an additional 143 shares during the period. Amalgamated Bank boosted its holdings in shares of Haemonetics by 5.7% in the second quarter. Amalgamated Bank now owns 7,322 shares of the medical instruments supplier’s stock valued at $289,000 after buying an additional 392 shares during the period. American Century Companies Inc. boosted its holdings in shares of Haemonetics by 0.9% in the second quarter. American Century Companies Inc. now owns 46,271 shares of the medical instruments supplier’s stock valued at $1,827,000 after buying an additional 425 shares during the period. The Manufacturers Life Insurance Company boosted its holdings in shares of Haemonetics by 1.2% in the second quarter. The Manufacturers Life Insurance Company now owns 39,906 shares of the medical instruments supplier’s stock valued at $1,575,000 after buying an additional 488 shares during the period. Finally, UBS Asset Management Americas Inc. boosted its holdings in shares of Haemonetics by 2.7% in the second quarter. UBS Asset Management Americas Inc. now owns 28,153 shares of the medical instruments supplier’s stock valued at $1,112,000 after buying an additional 742 shares during the period.

WARNING: “Mark W. Kroll Sells 7,118 Shares of Haemonetics Corporation (HAE) Stock” was originally published by Ticker Report and is the sole property of of Ticker Report. If you are accessing this article on another website, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The original version of this article can be read at https://www.tickerreport.com/banking-finance/3126608/mark-w-kroll-sells-7118-shares-of-haemonetics-corporation-hae-stock.html.

About Haemonetics

Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2018 Ticker Report. Google+.